© 2020 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2020 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
September 19, 2020
Isha Bangia, PharmD, MBA
Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.
September 16, 2020
The American College of Physicians (ACP) said many reforms are needed to install appropriate checks and balances in the biologic drugs marketplace.
A broader range of indications in rheumatology combined with a Canadian push for biosimilar acceptance bodes well for Merck's Brenzys product.
September 15, 2020
Courts have allowed biosimilar developers "safe harbor" against infringement suits, but there are limits, attorneys from Goodwin Proctor explain.
September 14, 2020
With anti–tumor necrosis factor (TNF) therapy showing promise in treating coronavirus disease 2019 (COVID-19), authors called for these agents to have a higher priority in research.
September 11, 2020
In the effort to find treatments for coronavirus disease 2019 (COVID-19) and related conditions, Celltrion Healthcare’s monoclonal antibody has shown promise in a phase 1 trial.
September 5, 2020
Sarfaraz K. Niazi, PhD
September 3, 2020
Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.
September 1, 2020
The Australia-based biosimilar company hopes to compete with blockbuster programmed death-1 (PD-1) inhibitor franchises owned by Merck and Bristol Myers Squibb.
A look at efforts biosimilar manufacturers are taking to develop treatments for coronavirus disease 2019 (COVID-19).